VeraChem’s protein-ligand binding free energy software VM2 used in study of ligand binding to Breast-Cancer-Gene 1 (BRCA1) C-Terminal (BRCT)

VeraChem’s protein-ligand binding free energy software VM2 used in the study “Characterization of Promiscuous Binding of Phosphor Ligands to Breast-Cancer-Gene 1 (BRCA1) C-Terminal (BRCT): Molecular Dynamics, Free Energy, Entropy and Inhibitor Design”, PLoS Comput Biol 12(8): e1005057. DOI:10.1371/journal.pcbi.1005057

VeraChem’s protein-ligand binding affinity software VM2 applied to the study of p38a MAP kinase

VeraChem’s protein-ligand binding affinity software VM2 applied to the study of p38a MAP kinase

VeraChem’s protein-ligand binding affinity prediction software package VM2 applied to the study of p38a MAP kinase. “Insights from Free-Energy Calculations: Protein Conformational Equilibrium, Driving Forces, and Ligand-Binding Modes”, Biophysical Journal 103(2): 342-351. DOI: 10.1016/j.bpj.2012.05.046

Paper describing VeraChem’s protein-ligand binding affinity software VM2 published

Paper describing VeraChem’s protein-ligand binding affinity software VM2 published

Paper describing VeraChem’s protein-ligand binding affinity method VM2 published. “Modeling Protein-Ligand Binding by Mining Minima”, Journal of Chemical Theory and Computation 6(11): 3540-3557. DOI: 10.1021/ct100245n